ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0075

Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
Abstract Number: 0315

Microvascular Abnormalities Are Present in Autonomic Dysfunction: Results of a Prospective Study
Abstract Number: 1110

Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
Abstract Number: 2213

Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis
Abstract Number: 0314

Microvascular Differences Between Acute and Chronic Cutaneous Graft versus Host Disease
Abstract Number: 1158

Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Abstract Number: 2189

Migratory Arthritis in Children: What Besides Rheumatic Fever?
Abstract Number: 1590

Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
Abstract Number: 1758

Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
Abstract Number: 0545

Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Abstract Number: 1772

Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death
Abstract Number: 1404

Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Abstract Number: 0163

Modification of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis, Clinically Amyopathic Dermatomyositis, and Immune-mediated Necrotizing Myopathy
Abstract Number: 2551

Modified Delphi Process to Propose an Equity Measurement Roadmap in Rheumatology
Abstract Number: 0042

Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].